Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Jurnal Respirasi (JR)

Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer Santoso, Agus Andreas; Pratiwi, Suryanti Dwi; Sugiri, Yani Jane; Al Rasyid, Harun; Listyoko, Aditya Sri
Jurnal Respirasi Vol. 11 No. 2 (2025): May 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.2.2025.140-146

Abstract

Introduction: Non-small cell lung cancer (NSCLC) was the primary cause of death in lung cancer. Tyrosine kinase inhibitors (TKIs) were one of the management options for NSCLC. Meanwhile, serum carcinoembryonic antigen (CEA) plays a crucial role in the diagnosis and prognosis of NSCLC patients. This study aimed to determine the effectiveness of epidermal growth factor receptor (EGFR)-TKI based on progression-free survival (PFS) and overall survival (OS) in NSCLC patients with common EGFR mutations. Methods: This retrospective cohort study used a total sampling method. The serum CEA level was measured before the initial treatment. Tyrosine kinase inhibitors therapy was monitored with PFS and OS. Statistical analysis for comparing prognosis in NSCLC among TKI groups used Kruskal-Wallis, analysis of variance (ANOVA), Mann-Whitney, and Spearman’s rho tests. A significant analysis referred to a p-value of <0.05. Results: The participants were 189 patients, consisting of 106 on gefitinib, 43 on erlotinib, and 40 on afatinib. The average PFS values in the gefitinib, erlotinib, and afatinib groups were 9.9±5.25, 8.77±4.53, and 12.83±7.02 months, respectively (p=0.016). Furthermore, there were no significant OS among the gefitinib (14.91±7.61 months), erlotinib (14.54±7.64 months), and afatinib group (15.51±8.13 months, p=0.867). There was a significant correlation between CEA levels and PFS (r=0.146; p=0.046) and between CEA levels and OS (r=0.223; p=0.004). Conclusion: Although afatinib may prolong PFS compared with gefitinib and erlotinib, it did not significantly impact OS. Increased serum CEA levels before treatment significantly improved PFS and OS. However, elevated CEA levels are usually associated with a poor prognosis in NSCLC.
Co-Authors Agus Tri Indah K Al Ghozi, Haidarul Ghalib Alawiyah, Sofy Amalia Suzianti Anungputri, Pramita Sari Anwar, Syuhaila Aqila Aqila, Aqila Araminta, Mita Permatasari Arisandi, Dimas Ferdian Arrahma, Nabila Aulia , Rachmat Aulia, Ashrafah Alaifhi Boy Nurtjahyo Damayanti, Ria Darus, Aliya Fatma Ulfani Denny Erica DEWI SARTIKA Diah Zakiah Djajalaksana, Susanthy Erdi Suroso Eviana Norahmawati Fadli, Muhammad Luqman Faturrohman, Dani Fauzi, Aqshal Fibra Nurainy Fitriana, Elly Gajah, Azizah Sabrina Handono Kalim Hasibuan, Ernida Hasibuan, Nurul Huda Hayati, Devi Humaira Helmi Ridho, Muhammad Holipah, Holipah Husnul Khotimah, Muti Imam, Cecilia Widijati Indraningtyas, Lathifa Indriati, Sukma Ivlatia, Siti Mahrami K, Khairunnisa Kamaluddin Kamaluddin Khusnah, Lailatul Kurniawan, Gladys Lestari, Mia Dwi Listyoko, Aditya Sri Lolita, Nona Lukman Hakim Maulana, Arjuna Dwi Muhammad Anshory, Muhammad Muhammad Nur Nadiyyana, Siti Nurul Hartini Nyoman Artha Megayasa, Nyoman Artha Otik Nawansih Perdana, Yudha Pranoto, Bono Pratiwi, Suryanti Dwi Putra, Ngakan Putu Parsama Putri, Bella Tiara Rahmayanti, Fida Ramadhan, Fitratul Ritonga, Dinda Nur Annisa Rusdiansyah Rusdiansyah Sabrina Aulia Rahma Safitri, Diyah Ayu Safitri, Linda Santoso, Agus Andreas Sari, Nadyra Sary, Linda Mareta Sazly, Syukron Setyawan, Ungky Agus Shinta Puspitarani, Karina Sitorus, Nurul Jumadissaniyah Soekarno, Hari Sony Agung Santoso, Sony Agung Sri Budhi Rianawati, Sri Budhi Sri Hidayati Stephanie Rengkung, Stephanie Sudono, Irfan Sugiri, Yani Jane Suryanto Sosrowidigdo Tanto Pratondo Utomo Teguh Setiawan Thontowi Djauhari Tiranda, Monica Florenza Udin Hasanudin Ulfianty, Adinda Saskia Salsabila Wahono, Cesarius Singgih Wahyuni, Shelly Wandana, Nina Wijaya, Emerson Suta Wisnu Satyajaya Yudhanto, Hendy Setyo Yuliandari, Puspita